Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study

Publication | Open Access

DOI Full Paper Access

Citations

References

2021

Year

Pascaline Boudou‐Rouquette, Jennifer Arrondeau, Claire Gervais, Jean-Philippe Durand, Elizabeth Fabre, Sixtine De Percin, Clémentine Villeminey, Anne-Catherine Piketty, Nathalie Rassy, Guillaume Ulmann,

EBioMedicine

Abstract

References